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Summary Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53
tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical
staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of
disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by
immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1,
and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the
50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and
differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-I P-glycoprotein) expression or response
to treatment. However, we observed a statistically significant difference between the high prevalence of
p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous
tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological
subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in
ovarian adenocarcinoma.
Mutations within the gene encoding the nuclear tumour-
suppressor protein, p53, represent the commonest genetic
change associated with human cancer detected to date
(reviewed in Levine et al., 1991). Although the precise func-
tion of normal p53 is not yet firmly established, it probably
acts as a transcription factor in regulating gene expression
during traverse of the cell cycle (see Levine et al., 1991; Lane,
1992). Loss ofp53 function through a variety ofmechanisms,
principally involving gene mutation and deletion, is thus
thought to be an essential prerequisite for tumorigenesis in
many cell types. A well-recognised property of mutant p53
protein is its prolonged half-life within the cell compared
with that of its normal (wild-type) counterpart (Gannon,
1990; Levine et al., 1991). Consequently, the cellular levels of
such mutant p53 are considerably higher than those of the
normal protein and mutant p53 can therefore be readily
detected by a variety of immunohistochemical staining tech-
niques (Levine et al., 1991). Elevation of p53 levels may also
occur through non-mutational mechanisms associated with
enhanced stabilisation of the protein or interruption of nor-
mal degradative pathways (Levine et al., 1991). Nevertheless,
positive staining for p53 generally provides a convenient
'marker' for the presence of a mutated p53 protein, which
greatly facilitates studies aimed at correlating the presence of
this mutant tumour suppressor with clinicopathological
features of disease.
In common with most other solid tumour types, ovarian
carcinomas frequently harbour mutations in the p53 gene
associated with elevated levels of protein detectable
immunohistochemically on frozen tissue sections (Marks et
al., 1991; Mazours et al., 1991; Eccles et al., 1992). Interest-
ingly, some of these studies have suggested possible prognos-
tic correlates associated with the presence of mutated p53.
Marks et al. (1991) reported a significant correlation between
p53 immunocytochemical staining and tumour cell ploidy
which is known to be related to tumour aggressiveness and
overall survival. Independently, Okamoto et al. (1991) noted
that while p53 gene mutation is detectable at a frequency of
around 30% in most histological subtypes (in agreement with
other published studies; Marks et al., 1991; Mazours et al.,
1991; Eccles et al., 1992) ovarian adenocarcinoma of the
clear cell subtype is notable for the low frequency of detec-
table mutations in the p53 gene (Okamoto et al., 1991).
The multidrug resistance gene, mdr-1, encodes a plasma
membrane glycoprotein (P-glycoprotein or gpl70) that is
expressed in both normal tissues and tumour cells (Endicott
& Ling, 1989; Goldstein et al., 1989). Murphy et al. (1992)
found that 13% of ovarian tumours expressed P-glyco-
protein, and recent data have shown that mutant, but not
wild-type, p53 protein transactivates the promoter region of
the mdr-1 gene (Chin et al., 1992). Since drug resistance is a
major clinical problem in the treatment of ovarian cancer, it
is important to establish whether there is any relationship
between p53 mutation and drug resistance in tumours prior
to chemotherapy.
In- the study reported here we examined a series of 50
ovarian epithelial carcinomas for the presence of p53 muta-
tion by immunohistochemical staining with the polyclonal
antibody CM1 (Bartkova et al., 1991) and by direct
nucleotide sequencing of PCR-amplified DNA in selected
cases. Our results reveal no relation between p53 status and
drug resistance but show a statistically significant association
between p53 mutation and serous versus mucinous histo-
logical subtypes of this disease.
Materials and methods
Patients
Fifty tumour samples were collected from patients undergo-
ing laparotomy in hospitals throughout the north-west of
England as part of their treatment for epithelial ovarian
cancer. Patients undergoing initial laparotomy were staged
according to the International Federation of Gynaecologists
and Obstetricians system (FIGO stage) (Shepherd, 1989) and
tumour samples taken along with normal peritoneal biopsies.
Forty samples were from patients undergoing initial staging
laparotomy and the other ten were taken from operations for
recurrent or residual tumour following chemotherapy. Sam-
ples of normal ovarian tissue were also taken from patients
undergoing oophorectomy for benign gynaecological disease
in the same geographical area. All material was collected and
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frozen immediately in liquid nitrogen prior to subsequent
storage at -80°C.
The histological type and grade were assigned to each
tumour by independent review by the North West Ovarian
Cancer Group pathologists.
Immunohistochemistry
When required, samples were thawed and then fixed in
Methacarn for 1 h at room temperature. They were then
embedded in paraffin and 4tm sections taken and mounted
on Cell-Tak subbed slides and dried at 36°C overnight. The
slides were initially dewaxed and air dried for 15min, then
washed with 0.5 M TBS (Tris-buffered saline) at pH 7.6
before blocking endogenous peroxidase activity with 1.5 M
sodium azide and 30% hydrogen peroxide. Following this the
samples were again washed in TBS and exposed to a 10%
solution of normal swine serum for 10 min at room
temperature. They were then exposed in sequence to the
primary antibody (CM1; Bartkova et al., 1991) for 1 h at
37°C, a further TBS wash, a 1:2400 solution of peroxidase-
conjugated swine anti-rabbit immunoglobulin solution for
30 min at 37°C and a further TBS wash. The slides were
developed using diaminobenzidine (0.5mgml-') with 0.1%
nickel chloride in TBS buffer for 10 min at room
temperature, followed by incubation for 10 min with the
same solution with the addition of 30% hydrogen peroxidase
(1 jlI ml-'). The slides were then washed in distilled water
and the silver intensification carried out as described by
Przepiorka and Myerson (1986) for 1 min. The slides were
finally washed three times in distilled water, counterstained
for 10s in Mayer's haematoxylin, dehydrated, cleared in
xylene and mounted with xylene-based coverslipping
medium. The evaluation of the staining was performed by a
single observer (J.R.). The tumours were designated positive
if obvious staining of two or more distinct areas of cells was
seen when compared with negative controls from consecutive
sections. This method of assessment was chosen initially
because of the known heterogeneous nature of the biopsy
samples with tumour and stromal tissue present. In all cases
where positive staining occurred, all tumour tissue present
showed some degree of staining. However, this ranged from
approximately 5% to 50% of the biopsy examined. All stain-
ing analyses were performed using negative control sections
of the tumours (using 1:1000 normal rabbit serum in place of
the primary antibody) in parallel with known positive control
tumour.
Initially a known p53-staining breast tumour was used as a
positive control to establish the technique on ovarian tumour
sections. When a clearly positive-staining ovarian tumour
was identified, this was then used as control for the subse-
quent screening of the tumour panel. This tumour was also
the first one in which we identified a mutation by sequencing
(tumour A, Figure 2).
Staining for mdr status using the MRK 16 antibody was
performed as described by Murphy et al. (1992).
PCR amplification and sequencing ofexons 5-8 ofthep53
gene
DNA was prepared from frozen biopsy samples by standard
methods of detergent lysis, proteinase K digestion and
phenol extraction as described previously (Deane & Norton,
1990). PCR amplification was performed using the following
primer pairs (in each case 5' and 3' primer respectively):
TTCAACTCTGTCTCCTTCCT and TTAACCCCTCCTCC-
CAGAGA for exons 5 and 6, AGGCGCACTGGCCTCA-
TCTT and TGTGCAGGGTGGCAAGTGGC for exon 7
and TTCCTTACTGCCTCTTGCTT and AGGCATAACT-
GCACCCTTGG for exon 8. A 1 fig aliquot of genomic
DNA was amplified with 1 llM of each primer in a reaction
mix comprising 67 mM Tris pH 8.8, 6.7 mM magnesium
chloride, 10 mM P-mercaptoethanol, 6.7 mM ethylenediamine-
tetracetic acid, 179 mg ml-' bovine serum albumin, 10%
dimethylsulphoxide and 1.5 mM dATP, dCTP, dGTP and
TTP, in a volume of 50gil. Following denaturation at 95°C
for 7 min, 1 unit of Taq polymerase (Boehringer Mannheim,
Germany) was added and the mixture was overlaid with
mineral oil. Thirty cycles of amplification, consisting of
denaturation at 94C (1 min), annealing at 54°C (1 min) and
elongation at 72°C (2 min), were followed by a final exten-
sion reaction at 72°C for 7 min. PCR-amplified DNA was
purified on 1.5% low melting temperature agarose and
sequenced directly on both strands, using Taq polymerase
and the same primers, essentially as previously described
(Deane & Norton, 1990). Sequencing reactions were analysed
on denaturing 6% polyacrylamide gels.
Results
Table I summarises the characteristics of the 50 ovarian
epithelial tumours examined for p53 staining with the poly-
clonal antibody CM1. As negative control we examined five
samples of normal ovarian tissue obtained from patients
undergoing oophorectomy for benign gynaecological condi-
tions. In addition, a further five samples of peritoneum from
patients with epithelial ovarian tumours (three with p53
overexpression and two not overexpressing p53) were
examined. These, together with the normal controls, were all
negative for p53 staining (data not shown). Of the 50 ovarian
tumours, 28 (56%) were positive for p53 staining (Table 1).
Typically the pattern of staining was nuclear localised, as
exemplified in Figure la.
Table I Correlation of p53 CMI antibody staining with
clinicopathological features of ovarian adenocarcinoma
Numbers of tumours
p53+ pS3- Total
Histological type
Serous 18 7 25
Mucinous 3 9 12
Endometrioid 6 5 11
Anaplastic 1 1 2
Differentiation
Well differentiated 8 9 17
Moderately differentiated 10 4 14
Poorly differentiated 10 9 19
FIGO stage
I 0 3 3
II 0 1 1
III 25 15 40
IV 3 3 6
Pre or post treatment
Pre-treatment 23 17 40
Post-treatment 5 5 10
Figure 1 Photomicrographs showing the typical staining by the
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Table II p53 codon mutations detected in ovarian
adenocarcinoma
Mutated Amino acid
Tumour codon Base change substitution
B 241 TCC+TAC Ser -Tyr
A 273 CGT+TGT Arg-oCys
C 273 CGT+TGT Arg-)Cys
A C G T A C G T
b
Figure 2 Autoradiography showing direct sequencing of PCR-
amplified p53 DNA. a, Tumour B (WT = wild-type) around
codon 241 (TCC-Ser, read on the opposite strand as GGA). b,
Tumours A and C around codon 273 (CGT-Arg, read on the
opposite strand as ACG). PCR-amplified DNA from the tumour
samples was sequenced directly using the 3' primers. The arrows
indicate the sites of mutation. In each figure, the lanes represent
A, C, G and T from left to right.
Table III Correlation ofp53 status in ovarian adenocarcinoma with
expression of mdr-1 P-glycoproteina
Numbers of tumours
p53+ pS3-
mdr+ 6 2
mdr- 15 14
Fisher's exact P = 0.42. aData on mdr-I staining are from Murphy
et al. (1992).
Table IV Correlation of p53 status with response to treatment in
ovarian adenocarcinoma
Numbers of tumours
p53+ pS3-
Responding 12 6
(complete and partial responses)
Not responding
(stable or progressive disease) 10 11
Fisher's exact P = 0.33.
The polyclonal antibody CMI has previously been shown
to detect p53 overexpression in testicular tumours with a
similar reliability to monoclonal antibody staining of frozen
tissue sections (Bartkova et al., 1991). Since we used CMl on
Methacarn-fixed, paraffin-embedded tissue sections in our
own study, it was important to show that the use of such
fixed sections did not lead to a significant false-negative rate.
Five tumours, all of which showed no detectable p53 staining
in Methacarn-fixed tissue, were stained using frozen tissue
sections and all were negative (data not shown).
In order to determine whether those cases in our series
expressing high levels of p53 protein also harboured mutant
p53 genes, exons 5-8 of the p53 gene were sequenced on
both strands using PCR-amplified DNA from four tumours
expressing high levels of p53 and from one with normal
(undetectable) levels of this protein. Point mutations within
conserved regions of exons 7 and 8 were seen in three of
these, all of which expressed elevated levels of p53 protein
(Figure 2, Table II). Two cases shared the same mutation in
codon 273 (cases A and C). In order to exclude the pos-
sibility that one or other of these mutations arose from
contamination of cellular DNA with PCR products, these
two cases were reanalysed by PCR and sequencing. The same
mutation at codon 273 (Table II) was again seen in both
cases. As can be seen in Figure 2, all three cases with
detectable p53 mutations also harboured wild-type p53
sequence consistent either with these mutations being present
on one allele only or with the presence of admixed stromal
cells containing only wild-type p53.
In 37 of the tumours examined, data were available on the
expression of mdr-I P-glycoprotein (Murphy et al., 1992). Of
these 37, only eight were mdr positive, as determined by
staining with the MRK 16 antibody. Two of these were,
however, p53 negative (Table III). A statistical analysis
(Fisher's exact) showed no significant difference in mdr
(gpl70) expression in p53-positive or -negative tumours.
As shown in Table I, there was no correlation between p53
overexpression and differentiation or stage of the tumours.
Similarly, when the incidence of cases overexpressing p53 was
compared between patients pre and post treatment, we
observed no significant difference between these groups
(Table I). Although all the p53-positive cases were from
FIGO stage III/IV patients, the number of stage I/II cases in
this study was too low to establish the significance of this
observation (Table I). Interestingly, when the distribution of
p53-positive and -negative cases was examined in the context
of histological tumour type (Table I) there was a statistically
significant difference (P=0.0237) between the serous and
mucinous tumours. Finally, we were unable to detect
significant association between p53 staining and response to
chemotherapy (Table IV).
Discussion
One objective in our studies was to establish the reliability of
detecting overexpression of p53 in ovarian tumours by using
the polyclonal antibody CM 1, which can be used on
Methacarn-fixed sections. The frequency of p53 protein
detection (56% of cases) was similar to that reported
previously in published studies employing either immuno-
histochemistry on frozen biopsies or DNA-based methods
(nucleotide sequencing or single-strand conformational
polymorphism) (Eccles et al., 1991; Marks et al., 1991;
Mazours et al., 1991). Three of four p53-positive tumours
were shown directly to harbour a mutant p53 gene by PCR
amplification and nucleotide sequencing. It is noteworthy
that all three cases with demonstrable p53 mutation also
displayed accompanying wild-type sequence. This would be
consistent with the mutation being present on one allele only
or, alternatively, a substantial proportion of cells in these
biopsy specimens may not harbour mutant p53. Although we
cannot distinguish between these possibilities, the recent
report by Okamoto et al. (1991) on 17p allele loss in eight
out of nine ovarian tumours harbouring mutant p53 would
strongly argue in favour of the latter explanation.
Consistent with previous studies (Eccles et al., 1991; Marks
et al., 1991; Mazours et al., 1991) we found no obvious
correlation between p53 status in ovarian tumours and prog-
nosis in terms of overall survival. However, within the
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different histological tumour types, a higher proportion of
serous carcinomas were positive for p53 staining than were
tumours of the mucinous type. This difference in incidence of
p53 overexpression may well reflect subtle differences in
aetiology and or epidemiology associated with these histo-
logical subtypes.
In the light of the recent report by Chin et al. (1992)
documenting transactivation of the mdr gene promoter by
mutant p53, we examined the relation between p53 staining
and expression of the mdr-1 P-glycoprotein, determined on
37 of this series of adenocarcinomas, some of which formed
part of a previous study (Murphy et al., 1992). Because of
the low frequency of expression of gpl7O in ovarian tumours
we were unable to establish a significant correlation between
mdr and p53 expression. However our data show that gpl7O
expression can be found in the absence of p53 overexpres-
sion, indicating that mutant p53 is probably not the sole
determinant ofinappropriate expression of the mdr protein in
ovarian tumours.
We also examined the relation between p53 staining and
response to chemotherapy. The representation ofp53-positive
cases was not significantly different between patients who
responded and those who did not, a finding also supported
by the lack of increase in the proportion of tumours which
stained positive for p53 following chemotherapy. These
observations suggest that, while mutant p53 may well play a
role in the development of mdr phenotype, there are addi-
tional factors of greater importance in determining the re-
sponse to chemotherapy.
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